Trastuzumab (trade name, Herceptin®) is a humanized IgG1 monoclonal antibody (mAb) that targets the human epidermal growth factor receptor family member HER2 and that has shown efficacy in the treatment of HER2 over-expressing breast and gastric cancers [1]. The gene discussed is ERBB2; the disease is gastric cancer.